Company intelligence / Profile preview
Aranda Pharma
Kuopio, Finlandarandapharma.com ↗
- Ownership
- Private
- Employees
- ~49
- Development stage
- Preclinical
01
Overview
ADA‑308, the lead candidate, has shown excellent efficacy in preclinical studies for androgenetic alopecia and acne compared to current standards, with a clean safety profile. In prostate cancer models—including enzalutamide-resistant lines—ADA‑308 demonstrated potent AR inhibition and robust antitumor activity in vitro and in vivo but was discontinued for this indication before clinical trials. No clinical results are available yet as all active programs remain preclinical.
- Therapeutic areas
- OncologyCardiovascularDermatology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Aranda Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aranda Pharma.